A Phase 1 interventional study of TAK-954 in Renal Impairment and Healthy Volunteers, sponsored by Takeda. Completed at 4 sites in 2 countries. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-08-25.
Sponsored by Takeda · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Renal Insufficiency by Takeda — 1 open to participants now, 1 under way, none of them phase 3. Renal Insufficiency · Takeda.
Among the 12 studies in Renal Insufficiency by Takeda, this one is the 8th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2017, is one of 7 in phase 1, and was the 8th registered.
1,414 studies on the registry are indexed under Renal Insufficiency; 147 are open to participants now.
Browse Renal Insufficiency studies →1 of the 12 studies in Renal Insufficiency by Takeda is open now, in 7 countries. Recruiting first, the newest first:
Takeda · Sites in Belgium, Estonia, France and 4 more countries
Ages 18+
By country, each count listing its studies:
Of the 93 Renal Insufficiency studies recruiting now, 49 (53%) set no upper age limit and 19 (20%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 32 is below the median of 40 across 1,062 interventional studies indexed under Renal Insufficiency.
Median enrollment 48 across the 11 interventional studies, 10 across the 1 observational. Of the 11 that completed or were terminated, 9 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
1 of the studies in Renal Insufficiency by Takeda that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06243731TakedaA Study of Maribavir in Adults With Kidney Failure Who Have a Cytomegalovirus (CMV) Infection After Transplantation | 2027-01-31 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies in Renal Insufficiency by Takeda, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the effect of varying degrees of renal function on the PK of TAK-954 following single-dose IV administration and to investigate the impact of hemodialysis on the PK of single IV doses of TAK-954.
The drug being tested in this study is called TAK-954. This study will evaluate the effect of varying degrees of renal function on the PK of TAK-954 following single-dose IV administration and to investigate the impact of hemodialysis on the PK of single IV doses of TAK-954.
The study will enroll approximately up to 40 participants. Participants will be enrolled in one of the 5 treatment groups based on their renal impairment which will be determined based on Cockcroft and Gault (CG) equation as follows:
All participants in groups A to D will receive a single dose of TAK-954 and two single doses in Group E.
Enrollment in Group B (Mild) and Group E (ESRD requiring dialysis) will be based on assessment of safety and available PK data from Group C and Group D respectively.
This multi-center trial will be conducted in Czech Republic and Hungary. The overall time to participate in this study is approximately 8 weeks. Participants in Groups A to D will remain confined to clinic for 3 days. For both treatments, participants in Group E requiring dialysis will remain confined to clinic for 3 days. All participants will make a final visit to the clinic 10-14 days after receiving their last dose for a follow-up assessment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Groups B to E: Participants who have stable RI, defined as no change in disease status, as documented by the participant's most recent CLcr assessment; serum creatinine must not vary more than approximately 30% from Screening to Day -1 to confirm stable disease. Participants should also be in good health commensurate with their renal status.
Exclusion Criteria:
All participants:
Groups B to E:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with normal renal function receive TAK-954 0.2 milligram (mg), infusion, intravenously in fasted state, once on Day 1 of a 6-day period.
Drug: TAK-954
Participants receive TAK-954 0.2 mg, infusion, intravenously in fasted state, once on Day 1 of a 6-day period.
Drug: TAK-954
Participants receive TAK-954 0.2 mg, infusion, intravenously in fasted state, once on Day 1 of a 6-day period.
Drug: TAK-954
Participants without hemodialysis or End-stage Renal Disease (ESRD) receive TAK-954 0.2 mg, infusion, intravenously in fasted state, once on Day 1 of a 6-day period.
Drug: TAK-954
Participants with hemodialysis receive TAK-954 0.2 mg, infusion, intravenously in fasted state, once on Day 1 of a 4-day period followed by a minimum 13-day washout period, further followed by TAK-954 0.2 mg, infusion, intravenously in fasted state, once on Day 1 of a 4-day period.
Drug: TAK-954
TAK-954 intravenous infusion.
Groups A, C and D; Cmax: Maximum Observed Plasma Concentration for TAK-954 (Total and Free)
Time frame: Day 1 pre-infusion and at multiple time points (up to 120 hours) post-infusion
Groups A, C and D; AUC(0-72): Area Under the Plasma Concentration-time Curve From Time 0 to 72 Hours Post-dose for TAK-954 (Free and Total)
Time frame: Day 1 pre-infusion and at multiple time points (up to 72 hours) post-infusion
Groups A, C and D; AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-954 (Free and Total)
Time frame: Day 1 pre-infusion and at multiple time points (up to 120 hours) post-infusion
Groups A, C and D; AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-954 (Free and Total)
Time frame: Day 1 pre-infusion and at multiple time points (up to 120 hours) post-infusion
Groups A, C and D; Ae: Amount of TAK-954 Excreted in Urine
Time frame: Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion
Group E; Ae: Amount of TAK-954 Excreted in Urine in Period 1
Time frame: Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion
Group E; Ae: Amount of TAK-954 Excreted in Urine in Period 2
Time frame: Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion
Groups A, C and D; Fe: Fraction of TAK-954 Excreted in Urine
Time frame: Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion
Group E; Fe: Fraction of TAK-954 Excreted in Urine in Period 1
Time frame: Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion
Group E; Fe: Fraction of TAK-954 Excreted in Urine in Period 2
Time frame: Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion
Groups A, C and D; CLR: Renal Clearance for TAK-954
Time frame: Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion
Group E; CLR: Renal Clearance for TAK-954 in Period 1
Time frame: Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion
Group E; CLR: Renal Clearance for TAK-954 in Period 2
Time frame: Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion
Group E; CLD: Clearance of Dialysate for TAK-954 in Period 2
Time frame: Day 1 pre-infusion and at multiple time points (up to 4 hours) post-infusion
Participants took part in the study at 4 investigative sites in Czech Republic and Hungary from 21 November 2017 to 09 August 2019.
| Milestone | Group A: Healthy Participants | Group C: Moderate Renal Impairment | Group D: Severe Renal Impairment Not Requiring Dialysis | Group E: ESRD Requiring Dialysis |
|---|---|---|---|---|
| Started | 8 | 8 | 9 | 7 |
| Completed | 8 | 8 | 9 | 7 |
| Not completed | 0 | 0 | 0 | 0 |
| nanogram per milliliter (ng/mL) | Group A: Healthy Participants | Group C: Moderate Renal Impairment | Group D: Severe Renal Impairment Not Requiring Dialysis |
|---|---|---|---|
| TAK-954 (Total) | 2.623 ± 12.8 | 2.536 ± 23.2 | 2.660 ± 17.6 |
| TAK-954 (Free) | 0.1270 ± 29.2 | 0.1282 ± 22.5 | 0.1572 ± 21.7 |
| hour*nanogram per milliliter (h*ng/mL) | Group A: Healthy Participants | Group C: Moderate Renal Impairment | Group D: Severe Renal Impairment Not Requiring Dialysis |
|---|---|---|---|
| TAK-954 (Total) | 22.25 ± 19.1 | 24.91 ± 22.9 | 28.62 ± 18.1 |
| TAK-954 (Free) | 1.078 ± 25.7 | 1.259 ± 25.1 | 1.690 ± 25.9 |
| h*ng/mL | Group A: Healthy Participants | Group C: Moderate Renal Impairment | Group D: Severe Renal Impairment Not Requiring Dialysis |
|---|---|---|---|
| TAK-954 (Total) | 24.39 ± 17.7 | 30.00 ± 20.0 | 34.28 ± 19.3 |
| TAK-954 (Free) | 1.184 ± 26.8 | 1.516 ± 24.3 | 2.025 ± 26.7 |
| h*ng/mL | Group A: Healthy Participants | Group C: Moderate Renal Impairment | Group D: Severe Renal Impairment Not Requiring Dialysis |
|---|---|---|---|
| TAK-954 (Total) | 25.43 ± 16.8 | 34.90 ± 16.2 | 38.59 ± 23.9 |
| TAK-954 (Free) | 1.234 ± 28.4 | 1.749 ± 24.8 | 2.320 ± 29.7 |
| milligram (mg) | Group A: Healthy Participants | Group C: Moderate Renal Impairment | Group D: Severe Renal Impairment Not Requiring Dialysis |
|---|---|---|---|
| Groups A, C and D; Ae: Amount of TAK-954 Excreted in Urine | 0.03797 ± 0.011633 | 0.01763 ± 0.0087713 | 0.01190 ± 0.0091124 |
| mg | Group E: ESRD Requiring Dialysis |
|---|---|
| Group E; Ae: Amount of TAK-954 Excreted in Urine in Period 1 | 0.0003489 ± 0.00021788 |
| mg | Group E: ESRD Requiring Dialysis |
|---|---|
| Group E; Ae: Amount of TAK-954 Excreted in Urine in Period 2 | 0.001240 ± 0.00062000 |
| percentage of TAK-954 dose | Group A: Healthy Participants | Group C: Moderate Renal Impairment | Group D: Severe Renal Impairment Not Requiring Dialysis |
|---|---|---|---|
| Groups A, C and D; Fe: Fraction of TAK-954 Excreted in Urine | 19.00 ± 5.8075 | 8.808 ± 4.3746 | 5.953 ± 4.5595 |
| percentage of TAK-954 dose | Group E: ESRD Requiring Dialysis |
|---|---|
| Group E; Fe: Fraction of TAK-954 Excreted in Urine in Period 1 | 0.1739 ± 0.10869 |
| percentage of TAK-954 dose | Group E: ESRD Requiring Dialysis |
|---|---|
| Group E; Fe: Fraction of TAK-954 Excreted in Urine in Period 2 | 0.6190 ± 0.30950 |
| liter per hour (L/h) | Group A: Healthy Participants | Group C: Moderate Renal Impairment | Group D: Severe Renal Impairment Not Requiring Dialysis |
|---|---|---|---|
| Groups A, C and D; CLR: Renal Clearance for TAK-954 | 2.629 ± 0.78762 | 1.255 ± 0.51478 | 0.6836 ± 0.56141 |
| L/h | Group E: ESRD Requiring Dialysis |
|---|---|
| Group E; CLR: Renal Clearance for TAK-954 in Period 1 | 0.03192 ± 0.017670 |
| L/h | Group E: ESRD Requiring Dialysis |
|---|---|
| Group E; CLR: Renal Clearance for TAK-954 in Period 2 | 0.08330 ± 0.041650 |
| L/h | Group E: ESRD Requiring Dialysis |
|---|---|
| Group E; CLD: Clearance of Dialysate for TAK-954 in Period 2 | 1.368 ± 30.0 |
Collected over Treatment emergent adverse events (TEAEs) are adverse events that started after the first dose of study drug and no more than 14 days after the last dose of study drug as Treatment 2 (up to Day 29) in Group A, C, and E), and Treatment 1 (up to Day 15) in for Group D. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group A: Healthy Participants | 0/8 (0%) | 0/8 (0%) | 1/8 (12.5%) |
| Group C: Moderate Renal Impairment | 0/8 (0%) | 0/8 (0%) | 2/8 (25%) |
| Group D: Severe Renal Impairment Not Requiring Dialysis | 0/9 (0%) | 0/9 (0%) | 2/9 (22.2%) |
| Group E: ESRD 1 Hour After Dialysis | 0/7 (0%) | 0/7 (0%) | 1/7 (14.3%) |
| Group E: ESRD 2 Hours Before Dialysis | 0/7 (0%) | 0/7 (0%) | 2/7 (28.6%) |
| Event | Group A: Healthy Participants | Group C: Moderate Renal Impairment | Group D: Severe Renal Impairment Not Requiring Dialysis | Group E: ESRD 1 Hour After Dialysis | Group E: ESRD 2 Hours Before Dialysis |
|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 1/8 | 1/8 | 2/9 | 1/7 | 2/7 |
| HeadacheNervous system disorders | 1/8 | 1/8 | 0/9 | 0/7 | 0/7 |
| Depressed level of consciousnessNervous system disorders | 0/8 | 1/8 | 0/9 | 0/7 | 0/7 |
The safety set consisted of all participants who were enrolled and received at least 1 dose of trial drug.
| Age, Continuous(years) | Group A: Healthy Participants | Group C: Moderate Renal Impairment | Group D: Severe Renal Impairment Not Requiring Dialysis | Group E: ESRD Requiring Dialysis | Total |
|---|---|---|---|---|---|
| Mean | 57.0 ± 15.62 | 70.6 ± 3.50 | 62.2 ± 11.03 | 52.6 ± 10.06 | 60.9 ± 12.38 |
| Sex: Female, Male(Participants) | Group A: Healthy Participants | Group C: Moderate Renal Impairment | Group D: Severe Renal Impairment Not Requiring Dialysis | Group E: ESRD Requiring Dialysis | Total |
|---|---|---|---|---|---|
| Female | 3 | 4 | 4 | 0 | 11 |
| Male | 5 | 4 | 5 | 7 | 21 |
| Ethnicity (NIH/OMB)(Participants) | Group A: Healthy Participants | Group C: Moderate Renal Impairment | Group D: Severe Renal Impairment Not Requiring Dialysis | Group E: ESRD Requiring Dialysis | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 8 | 8 | 9 | 7 | 32 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Group A: Healthy Participants | Group C: Moderate Renal Impairment | Group D: Severe Renal Impairment Not Requiring Dialysis | Group E: ESRD Requiring Dialysis | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 8 | 8 | 9 | 7 | 32 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Group A: Healthy Participants | Group C: Moderate Renal Impairment | Group D: Severe Renal Impairment Not Requiring Dialysis | Group E: ESRD Requiring Dialysis | Total |
|---|---|---|---|---|---|
| Czech Republic | 6 | 6 | 5 | 3 | 20 |
| Hungary | 2 | 2 | 4 | 4 | 12 |
| Weight(kilogram (kg)) | Group A: Healthy Participants | Group C: Moderate Renal Impairment | Group D: Severe Renal Impairment Not Requiring Dialysis | Group E: ESRD Requiring Dialysis | Total |
|---|---|---|---|---|---|
| Mean | 79.95 ± 7.773 | 75.95 ± 13.035 | 76.22 ± 14.457 | 82.39 ± 7.006 | 78.43 ± 11.072 |
| Body Mass Index (BMI)(kilogram per square meter (kg/m^2)) | Group A: Healthy Participants | Group C: Moderate Renal Impairment | Group D: Severe Renal Impairment Not Requiring Dialysis | Group E: ESRD Requiring Dialysis | Total |
|---|---|---|---|---|---|
| Mean | 26.88 ± 4.051 | 26.25 ± 4.166 | 27.33 ± 4.272 | 28.14 ± 2.673 | 27.13 ± 3.765 |
| Height(centimeter (cm)) | Group A: Healthy Participants | Group C: Moderate Renal Impairment | Group D: Severe Renal Impairment Not Requiring Dialysis | Group E: ESRD Requiring Dialysis | Total |
|---|---|---|---|---|---|
| Mean | 173.25 ± 9.706 | 170.25 ± 9.543 | 166.89 ± 9.519 | 171.00 ± 6.976 | 170.22 ± 8.965 |
2 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda makes patient-level, de-identified data sets and associated documents available for all interventional studies after applicable marketing approvals and commercial availability have been received (or program is completely terminated), an opportunity for the primary publication of the research and final report development has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.
Ran from Nov 2017 to primary completion in Aug 2019, 20 months.
Results were first posted in Aug 2020, 1 year after primary completion.
Of 213 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 20 months is above that.
Counting every sponsor, half of 231 studies reached it within 8 months; a quarter within 5 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Td-8954